FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

## STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

l	OMB APPRO	VAL
	OMB Number:	3235-0287
l	Estimated average burde	en
l	hours per response:	0.5

	Check this box if no longer subject										
)	Section 16. Form 4 or Form 5										
J	obligations may continue. See										
	Instruction 1(b).										

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

							,	,												
1. Name and Address of Reporting Person*  ROBIN SHERRINGTON							2. Issuer Name <b>and</b> Ticker or Trading Symbol  Xenon Pharmaceuticals Inc. [ XENE ]										cable) or	g Pers	son(s) to Iss	vner
(Last) (First) (Middle) 200 - 3650 GILMORE WAY							3. Date of Earliest Transaction (Month/Day/Year) 09/12/2019										r (give title ) P, Strategy & Inn		Other (s below) nnovation	респу
(Street) BURNABY A1						4. If Amendment, Date of Original Filed (Month/Day/Year)										lividual or Joint/Group Filing (Check Applicable  Form filed by One Reporting Person  Form filed by More than One Reporting  Person				
(City) (State) (Zip)						. 5.55														
		Tab	le I - No	n-Deriv	ative	Sec	curiti	ies Ac	quir	red, C	Disp	osed c	of, or B	enet	ficially	Owned	i .			
Da					2. Transaction Date (Month/Day/Year)			Execution Date,			Transaction Disp Code (Instr. 5)			Securities Acquired (A) o sposed Of (D) (Instr. 3, 4 a			int of es ally Following	Form (D) o	n: Direct r Indirect istr. 4)	7. Nature of Indirect Beneficial Ownership
									С	ode	v	Amount	(A) (D)	or F	Price	Reporte Transac (Instr. 3	tion(s)			(Instr. 4)
Common Shares 09/12/							2019			M		6,172	2 A	.   9	\$3.07 <sup>(1)</sup>	12	2,064		D	
Common Shares 09/12/							2019			F		1,868	3 Г	9	\$9.38 <sup>(2)</sup>	10	0,196		D	
		7	able II -									sed of				Owned				
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemdexecution if any (Month/Da	Date,		ransaction ode (Instr.		n of E		nte Exer ration I nth/Day	Date	ble and	7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		curity	3. Price of Derivative Security Instr. 5)	9. Number derivative Securities Beneficial Owned Following Reported Transactio (Instr. 4)	ly	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	Beneficial Ownership (Instr. 4)
					Code	v	(A)	(D)	Date Exer	cisable		xpiration ate	Title	or Nu of	nount mber ares					
Stock Option (Right to	\$3.07 <sup>(1)</sup>	09/12/2019			M			6,172		(3)	09	9/18/2019	Common Shares	6,	172	\$0.00	0		D	

## **Explanation of Responses:**

- 1. The exercise price was converted to U.S. dollars from \$3.74 CAD using the closing rate of exchange on the Bank of Canada on the date of grant. The actual exercise price is the Canadian dollar amount regardless of the exchange rate on the day of exercise.
- 2. Represents the closing price of the Company's common shares on September 11, 2019, which was converted to a Canadian dollar amount for purposes of net settlement calculations.
- 3. The shares subject to the option fully vested on December 31, 2012. The date the options became fully vested was incorrectly reflected on the Reporting Person's Form 3.

## Remarks:

/s/ Sherry Aulin, Attorney-infact 09/13/2019

\*\* Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.